跳至主要内容
临床试验/NCT05200000
NCT05200000已完成1 期

Evaluation of Wharton's Jelly Extract Eye Drops, Treated by the AMTRIX Process, in the Treatment of Chronic Keratitis

TBF Genie Tissulaire12 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2020年1月8日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
20
试验地点
12
主要终点
Absence of aggravated inflammatory signs, worsening of visual acuity or other side effect

研究概览

简要总结

The purpose of this open, non-comparative, multicenter trial is to assess the impact of eye drops made of Wharton's jelly extract in the treatment of chronic keratitis that failed available therapies.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men or women between 18 and 70 years old.
  • Persistent corneal ulceration.
  • Resistance to medical treatment for more than one month or recurrence after medical treatment.
  • Patient who underwent a wash-out period of 15 days with no use of eye drops with preservative.
  • Patient with dry eye treatments that can be kept: tear substitutes, cyclosporine.
  • Informed and consenting patient.
  • Patient affiliated to a social security system or beneficiary of such a system.

排除标准

  • Patient with active infectious or traumatic keratitis such as burns.
  • Patient with herpetic keratitis.
  • Patient currently wearing contact lens, including scleral lenses concomitant with the treatment.
  • Patient currently treated with NSAIDs in eye drops or any eye drops containing preservatives.
  • Patient treated with antibiotic, anti-viral or anti-parasitic eye drops; with autologous or allogeneic serum; with platelet derivatives; with eye drops claiming healing properties; with eye drops containing growth factors, hyaluronic acid or trehalose.
  • Patient with hypersensitivity to fluorescein.
  • Patient with identified causes for keratitis for which discontinuation of medical treatment is beneficial.
  • Monophthalmic patients.
  • Persons deprived of liberty by a judicial or administrative decision.
  • Adults who are subject to a legal protection measure or who are unable to express their consent.
  • Pregnant woman.

结局指标

主要结局

Absence of aggravated inflammatory signs, worsening of visual acuity or other side effect

时间窗: Through study completion - average of 40 days

Inflammatory signs evaluated using a composite score on 66 points. Duration and intensity are evaluated for secretion, dry eyes, tearing, foreign body sensation, fluctuating vision, photophobia, burning sensation and lids edema. Duration is evaluated from a scale from 0: never to 4: all the time. Intensity is evaluated from a scale from 0: slight to 2: severe. Localization and intensity are evaluated for conjunctival edema, conjunctival redness and neovascularization. Localization is evaluated on a scale from 0: no reaction to 4: reaction present in the whole eye

次要结局

  • Improvement of visual acuity(7 days, 15 days, 40 days)
  • Re-epithelialization of the cornea(7 days, 15 days, 40 days)
  • Improvement of dry eyes signs and symptoms(7 days, 15 days, 40 days)

研究者

发起方
TBF Genie Tissulaire
申办方类型
Industry
责任方
Sponsor

研究点 (12)

Loading locations...

相似试验